Sartorius, DE0007165631

JPMorgan keeps EUR 295 target for Sartorius stock

Published on 10/14/2026 at 14:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan kept EUR 295 target on October 12, 2026. Sartorius stock costs EUR 258.25 on October 14, 2026, 2.77 percent above Xetra's EUR 251.30 close.

Analyst view and reporting date

  • On October 12, 2026, JPMorgan retained an Overweight rating for Sartorius.
  • In the first half of 2026, group sales revenue rose 7.70 percent on an operational constant-currency basis.
  • Sartorius stock trades at EUR 258.25 at 1:50 p.m. CEST at Lang & Schwarz on October 14, 2026, 2.77 percent above the Xetra close of October 13, 2026.
Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern
Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius (ISIN DE0007165631) was trading at EUR 258.25 at Lang & Schwarz on October 14, 2026, at 1:50 p.m. CEST, 2.77 percent above the Xetra close of October 13, 2026 at EUR 251.30. On October 12, 2026, finanzen.ch reported that JPMorgan kept its Overweight rating and EUR 295 target for Sartorius ahead of the third-quarter results.

JPMorgan keeps EUR 295 target

The retained target puts the analyst reference EUR 36.75 above the Lang & Schwarz price, equivalent to 14.23 percent above the stock price. The rating was unchanged even as JPMorgan expected Sartorius to slightly exceed market expectations for the third quarter, according to the October 12 note.

The analyst view adds a clear benchmark ahead of the next report. Sartorius stock would need to rise EUR 36.75 from the October 14 Lang & Schwarz price to reach EUR 295, while the latest market quote remained below the target.

What does the target imply?

The business backdrop provides the numerical counterweight to the valuation discussion. In the first half of 2026, group sales revenue increased 7.70 percent on an operational basis in constant currencies, while the underlying EBITDA margin reached 30.30 percent, according to the Yahoo Finance transcript of the July 23, 2026 earnings call.

The same call said reported net profit rose 51.00 percent to EUR 122.00 million in the first half of 2026, with tariff-related customer compensation affecting reported revenue. The company retained full-year constant-currency sales growth guidance of 5.00 percent to 9.00 percent and an underlying EBITDA margin above 30.00 percent.

Third-quarter date is October 22

Sartorius lists the nine-month 2026 results conference call for October 22, 2026, at 1:00 p.m. CEST. Ahead of that date, analysts surveyed by finanzen.ch projected third-quarter revenue of EUR 895.90 million, compared with EUR 843.20 million in the prior-year quarter, a forecast increase of 6.25 percent.

Stock remains below its yearly high

The Lang & Schwarz price of EUR 258.25 stood EUR 13.65 below the 52-week high of EUR 271.90 and EUR 59.75 above the 52-week low of EUR 198.50 on October 14, 2026. The quote was therefore 5.02 percent below the 52-week high, while the market capitalization was EUR 17.9 billion.

The stock was trading at EUR 258.25 at Lang & Schwarz on October 14, 2026, at 1:50 p.m. CEST, 2.77 percent above the Xetra close of October 13, 2026 at EUR 251.30. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.

Sartorius stock facts

  • Company: Sartorius AG
  • ISIN: DE0007165631
  • WKN: 716563
  • Ticker: SRT3
  • Primary exchange: Xetra
  • Price Lang & Schwarz (as of October 14, 2026, 1:50 p.m. CEST): EUR 258.25
  • Change versus Xetra close: plus 2.77 percent
  • Xetra close (October 13, 2026): EUR 251.30
  • Market capitalization: EUR 17.9 billion (as of October 14, 2026)
  • 52-week range: EUR 198.50-EUR 271.90 (as of October 14, 2026)
  • Sector / Industry: Healthcare / Medical Instruments and Supplies
  • Index membership: MDAX
  • Next earnings date: October 22, 2026

Market context: Market report DAX.

More news and analyses on Sartorius stock

Disclaimer...

en | DE0007165631 | SARTORIUS | boerse | 70324415 | bgmi